Vigil Neuroscience said the Food and Drug Administration removed a partial clinical hold on its ongoing Phase 1 clinical trial of a treatment for Alzheimer's disease, VG-3927. The clinical-stage ...

In the United States and some countries other than Europe, Lilly owns exclusive development and commercialization rights to ...

Light pollution has been increasing rapidly since the 1970s, posing a threat to the health of humans and wildlife.

Alzheimer disease research is yielding breakthroughs with blood tests and brain scans that can enhance early diagnosis, while ...

Lawyers for Eli Lilly have notified healthcare providers that shortages of Mounjaro and Zepbound are effectively over, despite the FDA not ... company’s Alzheimer’s drug, donanemab, faces ...

So, at the risk of sounding like Churchill, I do believe that this is the beginning of the end of Alzheimer's.' And progress seems nearer than a decade away. A similar drug, donanemab, is just ...

LONDON—Britain’s drug regulator authorized the Alzheimer’s drug Leqembi on Thursday, saying it’s the first medicine to show some impact in slowing the progression of the neurodegenerative ...

Lycia Neumann, PhD, senior director of health services research at the Alzheimer's Association, was not involved in the study but commented on how it highlights regional disparities in the ...

They used a drug prediction algorithm to predict that ... Their top candidate was DNP, which has been approved since 1996 to treat Alzheimer’s. “Interestingly, clinical overdoses of DNP ...

The U.S. Food and Drug Administration on Monday approved the ... people with the more prevalent type 2 form of the disease. The FDA first signed off on the system, which automatically adjusts ...

Vericel Corp.’s Maci for repairing cartilage defects in the knee has been approved by the U.S. FDA via a supplemental biologics license application. Using a patient’s own cells cultured on a porcine ...